瑞卢戈利(一种新型口服促性腺激素释放激素拮抗剂)治疗子宫肌瘤相关疼痛症状:一项在日本女性中开展的随机、安慰剂对照3期研究
这项3期随机双盲安慰剂对照研究纳入65例有中重度子宫肌瘤相关疼痛的日本绝经前女性,每日口服瑞卢戈利40 mg(n=33)或安慰剂(n=32)12周。瑞卢戈利组在末次给药前28天内最大NRS评分≤1的患者比例高于安慰剂组(57.6% vs 3.1%),疼痛相关指标改善,治疗中出现的不良事件更常见(87.9% vs 56.3%),但停药率低且组间无差异。
要点
- 瑞卢戈利组最大NRS评分≤1的比例为57.6%,安慰剂组为3.1%。
- 瑞卢戈利组最大NRS评分为0的比例为48.5%,安慰剂组为3.1%。
- 治疗中出现的不良事件发生率瑞卢戈利组87.9%、安慰剂组56.3%,停药率低且组间无差异。
核心结论
- 瑞卢戈利改善了子宫肌瘤相关疼痛且耐受性良好。
研究设计与样本
- 3期、多中心、随机、双盲、安慰剂对照研究,纳入65例有中重度子宫肌瘤相关疼痛(最大NRS评分≥4)的日本绝经前女性,随机接受每日一次瑞卢戈利40 mg(n=33)或安慰剂(n=32)治疗12周。
主要发现
- 末次给药前28天内最大NRS评分≤1的患者比例:瑞卢戈利组57.6% vs 安慰剂组3.1%。
- 末次给药前28天内最大NRS评分为0的患者比例:瑞卢戈利组48.5% vs 安慰剂组3.1%。
- 末次给药前28天内无疼痛天数百分比:瑞卢戈利组96.4% vs 安慰剂组71.4%。
- 治疗中出现的不良事件发生率:瑞卢戈利组87.9% vs 安慰剂组56.3%,停药率低且组间无差异,大多数不良事件为轻至中度。
- 发生率≥10%的治疗中出现的不良事件包括潮热、子宫不规则出血、多汗、月经过多(与瑞卢戈利的作用机制一致)以及病毒性上呼吸道感染。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the efficacy and safety of the oral gonadotropin-releasing hormone receptor antagonist, relugolix, in patients experiencing uterine fibroid-associated pain. DESIGN: Phase 3, multicenter, randomized, double-blind, placebo-controlled study. SETTING: Medical centers. PATIENT(S): Premenopausal Japanese women (N = 65) experiencing moderate-to-severe uterine fibroid-associated pain with a maximum Numerical Rating Scale (NRS) score of ≥4 were randomized and completed the study. INTERVENTION(S): Once-daily 40 mg relugolix (n = 33) or placebo (n = 32) for 12 weeks. MAIN OUTCOME MEASURE(S): Primary end point: proportion of patients with a maximum NRS score of ≤1 during the 28-day period before the final dose of study drug. Secondary end points: proportion of patients with no pain (NRS = 0) and percentage of days without pain during the 28-day period before the final dose of study drug; adverse events. RESULT(S): More patients receiving relugolix versus placebo achieved a maximum NRS score of ≤1 during the 28-day period before the final dose of study drug (57.6% vs. 3.1%). Similarly, more patients receiving relugolix versus placebo achieved a maximum NRS score of 0 (48.5% vs. 3.1%) and experienced more days without pain (96.4% vs. 71.4%). More patients receiving relugolix versus placebo experienced treatment-emergent adverse events (TEAEs; 87.9% vs. 56.3%); however, the rate of treatment discontinuation was low and not different between groups. Most TEAEs were mild to moderate in intensity. TEAEs (≥10%) included hot flush, metrorrhagia, hyperhidrosis, and menorrhagia, consistent with relugolix's mechanism of action, and viral upper respiratory tract infection. CONCLUSION(S): Relugolix improved uterine fibroid-associated pain and was well tolerated. CLINICAL TRIAL REGISTRATION NUMBERS: NCT02655224. JAPIC CLINICAL TRIAL INFORMATION: JapicCTI-163127.
引用
- Osuga Y, Enya K, Kudou K, et al. Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women. Fertil Steril. 2019. PMID: 31594635. doi:10.1016/j.fertnstert.2019.07.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。